Evidence map›Paper›PMID 31023272›Full record

Trial reportBMC nephrology2019

Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial.

Marcelo Augusto Duarte Silveira, Flávio Teles, Andressa A Berretta, Talita R Sanches, Camila Eleutério Rodrigues, Antonio Carlos Seguro, Lúcia Andrade

4 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02766036 phase2completednot on this map

Propolis Effects on Proteinuria and Kidney Function in Patients With Chronic Kidney Disease

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2016 to 2018Enrolled32ConditionsChronic Kidney DiseasesArmsPropolis, Placebo
NCT04072341 phase1 / phase2completednot on this map

Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients: a Randomized Cross-over Trial.

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2019 to 2020Enrolled40ConditionsChronic Kidney Disease Requiring Chronic DialysisArmsPropolis Period (Green Propolis 250mg/day), Control Period
NCT04480593 phase2 / phase3completednot on this mapstarted 2020, after this paper: background citation

The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2020 to 2020Enrolled120ConditionsCovid19ArmsBrazilian Green Propolis Extract (EPP-AF), Standard care
NCT04800224 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2021 to 2021Enrolled200ConditionsCovid19, InflammationArmsStandardized Brazilian Green Propolis Extract, Placebo
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Antioxidants for adults with chronic kidney disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marcelo Augusto Duarte SilveiraDivision of Nephrology, University of São Paulo School of Medicine, São Paulo, SP, Av. Dr. Arnaldo, 455, 3° andar, sala 3310, CEP 01246-903, Brazil. marceloadsilveira@gmail.com.
Flávio TelesSchool of Medicine, Federal University of Alagoas, Maceió, Brazil.
Andressa A BerrettaLaboratory of Research, Development & Innovation, Apis Flora Industrial e Comercial Ltda, Ribeirão Preto, Brazil.
Talita R SanchesDivision of Nephrology, University of São Paulo School of Medicine, São Paulo, SP, Av. Dr. Arnaldo, 455, 3° andar, sala 3310, CEP 01246-903, Brazil.
Camila Eleutério RodriguesDivision of Nephrology, University of São Paulo School of Medicine, São Paulo, SP, Av. Dr. Arnaldo, 455, 3° andar, sala 3310, CEP 01246-903, Brazil.
Antonio Carlos SeguroDivision of Nephrology, University of São Paulo School of Medicine, São Paulo, SP, Av. Dr. Arnaldo, 455, 3° andar, sala 3310, CEP 01246-903, Brazil.
Lúcia AndradeDivision of Nephrology, University of São Paulo School of Medicine, São Paulo, SP, Av. Dr. Arnaldo, 455, 3° andar, sala 3310, CEP 01246-903, Brazil.
Universidade de São Paulo · BRApis Flora (Brazil) · BRUniversidade Federal de Alagoas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is a public health problem worldwide, and proteinuria is a well-established marker of disease progression in CKD patients. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties, as well as having been shown to have an antiproteinuric effect in experimental CKD. The aim of this study was to evaluate the impact of Brazilian green propolis extract on proteinuria reduction and the changes in the estimated glomerular filtration rate (eGFR).

methodsThis was a randomized, double-blind, placebo-controlled study including patients with CKD caused by diabetes or of another etiology, 18-90 years of age, with an eGFR of 25-70 ml/min per 1.73 m

resultsAt the end of treatment, proteinuria was significantly lower in the propolis group than in the placebo group-695 mg/24 h (95% CI, 483 to 999) vs. 1403 mg/24 h (95% CI, 1031 to 1909); P = 0.004-independent of variations in eGFR and blood pressure, which did not differ between the groups during follow-up. Urinary monocyte chemoattractant protein-1 was also significantly lower in the propolis group than in the placebo group-58 pg/mg creatinine (95% CI, 36 to 95) vs. 98 pg/mg creatinine (95% CI, 62 to 155); P = 0.038.

conclusionsBrazilian green propolis extract was found to be safe and well tolerated, as well as to reduce proteinuria significantly in patients with diabetic and non-diabetic CKD.

trial registration( ClinicalTrials.gov number NCT02766036. Registered: May 9, 2016).

Indexed as

PropolisProteinuriaRenal Insufficiency, ChronicAnti-Inflammatory AgentsAntioxidantsDisease ProgressionFemaleGlomerular Filtration RateHumansMaleMiddle AgedPlant ExudatesRenal EliminationTreatment OutcomeAnti-Inflammatory AgentsAntioxidantsPlant ExudatesPropolis

Identifiers

PMID31023272
PMCPMC6485062
OpenAlexW2947218170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.